RECRUITING

Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)

Conditions

Obsessive-Compulsive Disorder OCD Ketamine Naltrexone MRI Brain Imaging OCD symptoms

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to understand how ketamine works in the brain to bring about a reduction in OCD symptoms.

Official Title

Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)

Quick Facts

Study Start:2024-02-24

Study Completion:2028-11

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05940324

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 65 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Ages 18-65 * Meet the criteria for OCD diagnosis * Failed at least 1 prior trial of standard first-line OCD treatment * Agree to the following lifestyle modifications: comply with requirements for fasting prior to the Experimental Session, not enroll in any other interventional clinical trials during the duration of the study, and commit to medication study procedures. * Able to provide informed consent	* prior naltrexone or ketamine use/exposure * Any current or past medical/psychiatric condition that makes participation unsafe in the opinion of the investigator or study physician * Pregnant or nursing, or able to become pregnant and are not practicing an effective means of birth control * the presence of metal in the body that is contraindicated for MRI scans

Inclusion Criteria

Exclusion Criteria

* Ages 18-65
* Meet the criteria for OCD diagnosis
* Failed at least 1 prior trial of standard first-line OCD treatment
* Agree to the following lifestyle modifications: comply with requirements for fasting prior to the Experimental Session, not enroll in any other interventional clinical trials during the duration of the study, and commit to medication study procedures.
* Able to provide informed consent

* prior naltrexone or ketamine use/exposure
* Any current or past medical/psychiatric condition that makes participation unsafe in the opinion of the investigator or study physician
* Pregnant or nursing, or able to become pregnant and are not practicing an effective means of birth control
* the presence of metal in the body that is contraindicated for MRI scans

Contacts and Locations

Study Contact

Pavithra Mukunda, MS

CONTACT

6504972578

ocdresearch@stanford.edu

Carolyn I Rodriguez, MD, PhD

CONTACT

(650) 723-6158

ocdresearch@stanford.edu

Study Locations (Sites)

Department of Psychiatry & Behavioral Sciences

Stanford, California, 94305

United States

Collaborators and Investigators

Sponsor: Stanford University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-02-24

Study Completion Date2028-11

Study Record Updates

Study Start Date2024-02-24

Study Completion Date2028-11

Terms related to this study

Keywords Provided by Researchers

OCD
Ketamine
Naltrexone
MRI
Brain Imaging
OCD symptoms
Obsessive-Compulsive Disorder

Additional Relevant MeSH Terms

Obsessive-Compulsive Disorder